GenWay and Beckman form biomarker discovery pact :
This article was originally published in Clinica
GenWay Biotech is to provide Beckman Coulter with access to its method for enhancing the detection of biomarkers and drug targets, under an exclusive licensing deal formed between both parties. The method, IgY technology, selectively partitions the 12 most abundant proteins - up to 96% of the protein mass - from human serum or plasma. Because highly abundant plasma proteins are the main cause of assay noise, and may interfere with the detection of important biomarkers and drug targets, this technology could significantly facilitate the discovery of novel proteins, explained San Diego, California-based GenWay.
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.